In Brief: OTC vaginal contraceptives
This article was originally published in The Tan Sheet
Executive Summary
OTC vaginal contraceptives: American College of Nurse-Midwives tells FDA that removal of OTC status for vaginal contraceptives should not be undertaken "without strong evidence that these products pose a significant hazard to the health of their users." The Association for the Advancement of Health Care, in separate comments on FDA's proposal to require NDAs/ANDAs for OTC contraceptives, said FDA's proposal is "ill-advised" and will have a "negative impact" on availability of "affordable, reliable contraceptive options." Other industry and health professionals groups also have opposed the proposal ("The Tan Sheet" June 19, pp. 9-12)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning